Follow-up results from the phase 3 EMBER-3 study showed that, as a monotherapy, Inluriyo demonstrated a 38% reduction in the ...

What’s holding pharma back from true digital transformation? At NEXT Pharma 2025, Our CEO Rob Verheul and Roeland van der ...

Galderma’s Nemluvio (nemolizumab) has shown rapid relief of itch, as well as improvement in sleep, in patients with atopic ...

Virtual Works was founded in 1997 as a formal co-operative of independent professionals, all highly experienced and with a collective and complementary skills base. All of us have been working in ...